- Patent Title: Anti-TIGIT antibodies and their use as therapeutics and diagnostics
-
Application No.: US16958262Application Date: 2018-12-29
-
Publication No.: US11214616B2Publication Date: 2022-01-04
- Inventor: Tong Zhang , Liu Xue , Qi Liu , Min Wei , Kang Li
- Applicant: BEIGENE, LTD.
- Applicant Address: KY Grand Cayman
- Assignee: BEIGENE, LTD.
- Current Assignee: BEIGENE, LTD.
- Current Assignee Address: KY Grand Cayman
- Agency: Cooley LLP
- Priority: WOPCT/CN2017/120392 20171230
- International Application: PCT/CN2018/125375 WO 20181229
- International Announcement: WO2019/129261 WO 20190704
- Main IPC: C07K16/00
- IPC: C07K16/00 ; A61K39/00 ; C07K16/28 ; A61K45/06
Abstract:
Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.
Public/Granted literature
- US20200331999A1 ANTI-TIGIT ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS Public/Granted day:2020-10-22
Information query
